Neutrophils have been observed to infiltrate HER2+ tumors and contribute to the development of resistance to HER2-targeted therapies, such as trastuzumab.[93,94] They may facilitate resistance through the secretion of factors that promote tumor growth and suppress the immune response against the cancer cells. This evidence concerns the gene ERBB2 and neoplasm.